LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $94.57.

Several brokerages have commented on LMAT. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Oppenheimer reissued an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LMAT. Conestoga Capital Advisors LLC grew its stake in LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares in the last quarter. Copeland Capital Management LLC grew its position in shares of LeMaitre Vascular by 1.0% during the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares in the last quarter. State Street Corp grew its position in shares of LeMaitre Vascular by 3.6% during the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after buying an additional 28,525 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of LeMaitre Vascular by 2.6% during the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after buying an additional 18,295 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 4.5% in the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after acquiring an additional 23,443 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $92.12 on Monday. LeMaitre Vascular has a one year low of $52.88 and a one year high of $109.58. The company’s fifty day moving average price is $97.75 and its 200-day moving average price is $90.07. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 50.34, a PEG ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same period in the previous year, the business earned $0.33 earnings per share. The business’s revenue was up 15.6% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.